Lipid sink (toxin sequestration mechanism)

The “lipid sink” refers to a pharmacological mechanism and not a discrete biological macromolecule or cellular target. It is a widely accepted explanation for how intravenous lipid emulsions reverse systemic toxicity caused by highly lipophilic drugs, such as local anesthetics and certain opioids. The lipid sink model posits that intravenous lipid emulsion (e.g., Intralipid) introduced into the bloodstream acts as a lipid phase or “sink,” absorbing and sequestering circulating lipophilic toxins. This sequestration reduces the concentration of toxic drug in target tissues (like the heart and central nervous system), facilitating redistribution and metabolism, thus reversing toxic effects and improving patient outcomes. The mechanism is important in clinical toxicology and anesthesiology but is not a molecular drug target in the conventional sense of a receptor, enzyme, or transporter[1][3][4][5][2]. Critical note: “Lipid sink/toxin sequestration” is a therapeutic mechanism and not a molecular target. It does not conform to standard drug target categories (it is not a receptor, enzyme, channel, or gene product), so fields like canonical name, abbreviation, and family should be considered non-applicable or flagged for revision in any structured database.

Other names

Lipid sinkLipid shuttleLipid emulsion therapyToxin sequestration by lipid emulsion

Sequestration of lipophilic drugs from target tissues into an intravascular lipid phase, Redistribution of lipophilic toxins away from organs, Reduction in free (unbound) toxic drug concentrations